Two lawsuits have been filed against Anthem Blue Cross for denying coverage to 2 women for the hepatitis C medication Harvoni.
Two lawsuits have been filed against Anthem Blue Cross for denying coverage to 2 women for the hepatitis C medication Harvoni. Both lawsuits claim the insurer denied coverage for Harvoni, because the amount of liver damage sustained by the women was insufficient to warrant payment for the drug, and the treatment was not medically necessary.
The arguments go back and forth. In its denial letter sent to 1 of the plaintiffs, Anthem said that the women's liver had not yet sustained enough damage. The plaintiff argues that preventing her liver from getting to that stage would be the point of her treatment.
Read the complete report on The Wall Street Journal: http://on.wsj.com/1FUq4Eu
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More